| __timestamp | Halozyme Therapeutics, Inc. | Telix Pharmaceuticals Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 22732000 | 22622695 |
| Thursday, January 1, 2015 | 29245000 | 24863028 |
| Friday, January 1, 2016 | 33206000 | 21351001 |
| Sunday, January 1, 2017 | 31152000 | 53837297 |
| Monday, January 1, 2018 | 10136000 | 16080096 |
| Tuesday, January 1, 2019 | 45546000 | 18525736 |
| Wednesday, January 1, 2020 | 43367000 | 2024000 |
| Friday, January 1, 2021 | 81413000 | 2548000 |
| Saturday, January 1, 2022 | 139304000 | 61556000 |
| Sunday, January 1, 2023 | 192361000 | 188157000 |
| Monday, January 1, 2024 | 159417000 |
Igniting the spark of knowledge
In the dynamic world of biotechnology, understanding the cost of revenue is crucial for evaluating a company's financial health. This analysis focuses on Halozyme Therapeutics, Inc. and Telix Pharmaceuticals Limited, two prominent players in the industry. Over the past decade, Halozyme has seen a staggering 747% increase in its cost of revenue, peaking in 2023. Meanwhile, Telix Pharmaceuticals experienced a dramatic surge of 8,215% in the same period, highlighting its rapid growth trajectory. Notably, both companies faced fluctuations, with Halozyme's cost of revenue dipping in 2018 and Telix's in 2020. These trends underscore the volatile nature of the biotech sector, where strategic investments and market dynamics play pivotal roles. As we move forward, monitoring these financial metrics will be essential for investors and stakeholders aiming to navigate the complexities of the biotech landscape.
Cost Insights: Breaking Down Eli Lilly and Company and Telix Pharmaceuticals Limited's Expenses
Cost of Revenue Comparison: AbbVie Inc. vs Halozyme Therapeutics, Inc.
Analyzing Cost of Revenue: Biogen Inc. and Telix Pharmaceuticals Limited
Cost of Revenue Trends: Neurocrine Biosciences, Inc. vs Halozyme Therapeutics, Inc.
Analyzing Cost of Revenue: Intra-Cellular Therapies, Inc. and Halozyme Therapeutics, Inc.
Cost Insights: Breaking Down Jazz Pharmaceuticals plc and Halozyme Therapeutics, Inc.'s Expenses
Halozyme Therapeutics, Inc. vs Lantheus Holdings, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Halozyme Therapeutics, Inc. vs Cytokinetics, Incorporated
Cost of Revenue Comparison: Halozyme Therapeutics, Inc. vs Wave Life Sciences Ltd.
Cost Insights: Breaking Down Halozyme Therapeutics, Inc. and Viridian Therapeutics, Inc.'s Expenses
Cost Insights: Breaking Down Telix Pharmaceuticals Limited and Ionis Pharmaceuticals, Inc.'s Expenses
Cost of Revenue Comparison: Telix Pharmaceuticals Limited vs PTC Therapeutics, Inc.